Showing Form 4 filings for RLAY
Pre-configured institutional-grade criteria for instant high-conviction screening
Multiple insiders buying stock within the last 30 days
Direct open-market purchases by Chief Executive Officers
Financial chiefs and top corporate officers accumulating shares
Institutional-scale insider purchases of $1,000,000 or greater
Insiders increasing their overall equity ownership by over 20%
High-value executive divestments by CEOs and CFOs over $1M
Relay Therapeutics, Inc.
Price
$18.62
Shares
753
Ownership
222,904
Value/Share
Rahmer Peter
See remarks
Unknown
Industry
2,252
396,878
Bergstrom Donald A
Pres, R, D
1,469
103,665
Catinazzo Thomas
CFO